A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

INTRODUCTION: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated. METHODS: In a phase 1b st...

Descripción completa

Detalles Bibliográficos
Autores principales: Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Angevin, Eric, Hong, David S., Rybkin, Igor I., Barve, Minal, Bauer, Todd M., Delmonte, Angelo, Dunbar, Martin, Motwani, Monica, Parikh, Apurvasena, Noon, Elysa, Wu, Jun, Blot, Vincent, Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717236/
https://www.ncbi.nlm.nih.gov/pubmed/35005654
http://dx.doi.org/10.1016/j.jtocrr.2021.100262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717236/
https://www.ncbi.nlm.nih.gov/pubmed/35005654
http://dx.doi.org/10.1016/j.jtocrr.2021.100262

Ejemplares similares